NEW YORK (
) has been downgraded by TheStreet Ratings from buy to sell. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time.
VirtualScopics, Inc. provides imaging solutions for clinical trials serving the pharmaceutical, biotechnology, and medical device industries. The company has a P/E ratio of 52, equal to the average diversified services industry P/E ratio and above the S&P 500 P/E ratio of 22.6. VirtualScopics has a market cap of $68.4 million and is part of the
industry. Shares are up 3.3% year to date as of the close of trading on Thursday.
You can view the full
or get investment ideas from our